Cytogenix selects new candidate for development

CytoGenix plans to commence the preclinical development of CY403, an antibacterial agent against all strains of Staphylococcus aureus and, in particular, against "superbugs" such as methicillin-resistant and vancomycin-resistant S aureus.

According to Yin Chen, the Houston, Texas, USA-headquartered firm's chief scientific officer, "the introduction of CY403 into the preclinical product development phase within three months after target discovery and validation demonstrates the true value of our gene silencing technology. We have the capability to move very efficiently from discovery to product candidate in a matter of a few months."

She went on to say that "recent laboratory studies show that this compound rapidly kills MRSA and prevents further growth. Evidence shows that this compound is a powerful bactericidal as well as a bacteriostatic agent against MRSA. Further studies will confirm these capabilities in animal and human trials."